Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAS1 | P04201 | 1/20 | 0.55 |
| ▸ | AGTR2 | P50052 | 16/20 | 0.50 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3909393 | 0.93 | MAS1 (0.65) | MAS1AGTR2AGTR1MEN1GMNN | |
| SCHEMBL3975298 | 0.92 | AGTR2 (0.48) | MAS1AGTR2AGTR1 | |
| SCHEMBL4101355 | 0.91 | MAS1 (0.57) | MAS1AGTR2AGTR1MEN1GMNN | |
| SCHEMBL3973010 | 0.90 | MAS1 (0.57) | MAS1AGTR2AGTR1MEN1GMNN | |
| SCHEMBL4099345 | 0.88 | MAS1 (0.66) | MAS1AGTR2AGTR1MEN1GMNN | |
| SCHEMBL7383678 | 0.88 | MAS1 (0.55) | MAS1AGTR2AGTR1MEN1GMNN | |
| SCHEMBL3915251 | 0.86 | MAS1 (0.69) | MAS1AGTR2AGTR1MEN1GMNN | |
| SCHEMBL3905659 | 0.86 | MAS1 (0.55) | MAS1AGTR2AGTR1MEN1GMNN | |
| SCHEMBL29769813 | 0.86 | MAS1 (0.55) | MAS1AGTR2AGTR1MEN1GMNN | |
| SCHEMBL24637554 | 0.85 | AGTR2 (0.67) | MAS1AGTR2AGTR1MEN1GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1185527-B1 | 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | AVENTIS PHARMA GMBH (DE) | 2005-07-27 | — | — | EP | claimed |
| JP-2002544130-A | — | — | 2002-12-24 | — | — | JP | claimed |
| US-20020077344-A1 | 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical prepartions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2002-06-20 | — | — | US | claimed |
| EP-1185527-A1 | 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | Aventis Pharma Deutschland GmbH (DE) | 2002-03-13 | — | — | EP | claimed |
| US-20010018449-A1 | 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2001-08-30 | — | — | US | claimed |
| US-6235766-B1 | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-05-22 | — | — | US | claimed |
| WO-2000068226-A1 | 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-16 | — | — | WO | claimed |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | CAPACITY BIO INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12343331-B2 | Methods and agents that stimulate mitochondrial turnover for treating disease | Capacity Bio, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4284779-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-117120417-A | Methods and agents for stimulating mitochondrial turnover to treat diseases | 容量生物公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2022165189-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20220233507-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. | 2022-07-28 | — | — | US | disclosed |
| EP-1185527-B1 | 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | AVENTIS PHARMA GMBH (DE) | 2005-07-27 | — | — | EP | disclosed |
| US-6429222-B2 | HYPOTENSIVE AGENT, ENDOTHELIAL DAMAGE, ARTERIOSCLEROSIS, ANTIDIABETIC AGENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-08-06 | — | — | US | disclosed |
| US-20020077344-A1 | 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical prepartions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2002-06-20 | — | — | US | disclosed |
| EP-1185527-A1 | 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | Aventis Pharma Deutschland GmbH (DE) | 2002-03-13 | — | — | EP | disclosed |
| US-20010018449-A1 | 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2001-08-30 | — | — | US | disclosed |
| US-6235766-B1 | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-05-22 | — | — | US | disclosed |
| WO-2000068226-A1 | 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12343331-B2 | Methods and agents that stimulate mitochondrial turnover for treating disease | NLN, MAVS, PINK1 | MAS1 266/4885AGTR2 337/4885AGTR1 242/4885 |
| US-20220233507-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | NLN, MAVS, PINK1 | MAS1 266/4885AGTR2 337/4885AGTR1 242/4885 |
| US-20010018449-A1 | 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical preparations comprising them | AGTR1, NPR1, EDNRB | MAS1 362/4885AGTR2 7/4885AGTR1 1/4885 |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | MDH2, NLN, PINK1 | MAS1 911/4885AGTR2 1203/4885AGTR1 1006/4885 |
| US-20020077344-A1 | 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical prepartions comprising them | AGTR1, NPR1, EDNRB | MAS1 427/4885AGTR2 8/4885AGTR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.